SUMMARY -Chronic obstructive pulmonary disease (COPD) and heart failure (HF) both are global epidemics with substantial burden on morbidity and mortality. Th ey present major challenges to healthcare providers and often coexsist. Multiple interactions exist between these conditions. COPD is often responsible for delayed diagnosis of HF and vice versa, since both conditions have similar symptoms such as dyspnea and poor exercise tolerance based on the skeletal myopathic response rather than the primary organ failure. Patients with COPD also have an increased risk of developing HF and higher hospitalization and death rates compared with HF patients without COPD. Echocardiography and pulmonary function tests along with natriuretic peptides should be performed and carefully interpreted. Diagnostic assessment of both conditions present in the same patient is often diffi cult, but therapeutic approach is also often non-adherent to current guidelines. For example, patients with coexisting COPD and HF receive beta-blockers at disappointingly low rates below 20%. Closer collaboration between cardiologists and pulmonologists is required for better identifi cation and management of concurrent COPD and HF.
Introduction
Chronic obstructive pulmonary disease (COPD) is projected to be the fi fth leading cause of morbidity and third leading cause of mortality worldwide by 2020 1 . Although major advances in the understanding of COPD have been made in recent decades, the heterogeneity of clinical phenotypes, as well as the variability of clinical course continue to be only partially explained. Th e Global Initiative for Chronic Obstructive Lung Disease (GOLD) was launched in 1997 in order to improve the understanding of the underlying mechanisms of the disease and global awareness of COPD, as well as to reach expert recommendation on the prevention, diagnosis and treatment of COPD. In the fi rst GOLD Workshop Summary Report in 2001, COPD is defi ned as a disease state characterized by airfl ow limitation that is not fully reversible and is usually progressive. It has also been stated that the disease is associated with an abnormal infl ammatory response of the lungs to noxious particles or gases.
Th e initial COPD ranking system was based on post-bronchodilator spirometry and it has been proven as a useful indicator for treatment, as well as a reliable value to be compared in clinical studies. In other words, in the beginning of our understanding of COPD, the rigidity (and simplicity) of the staging system proved useful. However, it has become evident that the relationship between forced expiratory volume in the fi rst second (FEV 1 ) and symptoms is far from perfect and that exacerbations are independently associated with a more rapid function decline and increased mortality risk. Moreover, it seems that high symptom scores may originate not only from airfl ow limitation, but also from comorbidities. For example, in the ECLIPSE study, a subgroup of patients with the highest prevalence of comorbidities also had signs of persistent systemic infl ammation 2 . Consequently, the GOLD Science Committee adopted the novel approach to annual reviews of the ever growing published data with two major revisions of the GOLD document in 2007 and 2011. Th e GOLD 2011 assessment proposal includes two additional major criteria: the impact of the disease as perceived by the patient and the risk of future exacerbations. Patients are divided into four major categories: less symptoms and low risk (group A), more symptoms and low risk (group B), less symptoms and high risk (group C) and more symptoms and high risk (group D) 3 .
In clinical practice, the list of variables to be included in comprehensive approach to the individual patient is even longer, including lifestyle characteristics such as persistent smoking or the level of physical activity, biological markers of the disease activity and, very important, additional clinical outcomes such as comorbidities or lung hyperinfl ation.
COPD and Heart Failure
Chronic obstructive pulmonary disease is the fourth commonest cause of death worldwide, and the future does not seem bright, as by the year 2020 COPD will be ranked third. COPD and chronic heart failure (CHF) are both global epidemics and have common determinants (smoking and chronic infl ammation), which have been shown to play major roles in the pathogenesis of both diseases. Patients with COPD die mainly from non-respiratory diseases: 25% from cardiovascular diseases, 20%-33% from cancer (mainly lung cancer), and 4%-35% from respiratory diseases, mainly respiratory failure during exacerbations 4 . Among the comorbid conditions associated with CHF, COPD is one that most often delays correct diagnosis of CHF and is responsible for nonadherence to current treatment guidelines, such as beta blockade. On the other hand, until recently it was often enough that only self-reported COPD was considered sufficient to establish the diagnosis. Still, few reports have addressed this often ignored combination, and fewer still from the pneumonologist's point of view.
Prevalence of Coexisting COPD and CHF
In most studies, the estimated prevalence of COPD in patients with CHF ranges from 11% to 52% [5] [6] [7] [8] [9] [10] [11] [12] . In recent studies, the prevalence is notably higher. Th e risk ratio of developing heart failure (HF) is 4.5 (95% confidence interval (95% CI) 4.25-4.95) in COPD patients after adjustment for cardiovascular risk factors and compared with age-matched controls 13 . In the ECLIPSE study, the overall prevalence of HF was 7%, but it increased with the severity of airfl ow limitation 14 . At least part of the explanation, besides the common risk factors and a rich body of evidence for chronic systemic infl ammation and endothelial dysfunction, lies in global aging of the population; almost half of the people aged ≥65 have at least three medical conditions 15 . All these epidemiological data must be considered with some degree of caution because of the reported signifi cant disparities in using confi rmatory diagnostic tests amongst practicing clinicians. Up to one-third of patients labeled with COPD do not fulfi ll GOLD criteria for the diagnosis. A recent US study showed that among 219 patients discharged from a tertiary centre with both diagnoses of COPD and HF, 82% received echocardiography, as opposed to only 36% of patients who received pulmonary function testing, which is much less expensive and time consuming than comprehensive echocardiography 16 . In their prospective REPENSAR study, Macchia et al. found that only 6.5% of cardiologists and 12% of pulmonologists had certifi ed or ruled out COPD in patients with CHF, or vice versa 17 . COPD independently predicted failure of the ejection fraction of left ventricle (EFLV) assessment by echocardiography during hospital stay in the Italian TEMISTOCLE study 18 . Chronic obstructive pulmonary disease strongly predicts hospitalization rate and duration, and non-cardiovascular mortality in HF patients with 5-year mortality as high as 69% compared to 58% in patients without COPD. Also, respiratory infections are associated with cardiac decompensation in 10%-16% of admissions 19 . On the other hand, the prevalence of unrecognized HF in COPD patients presenting to emergency department with acute dyspnea is 20.9%, and unrecognized HF is a frequent cause of weaning diffi culties in COPD patients requiring mechanical ventilation due to severe acute exacerbation of the disease 20 .
Typical Clinical Feature: Dyspnea
Dyspnea is the most disabling symptom of COPD, which originates from decrease in the capacity of re-spiratory muscles to meet an increased mechanical load. Several diff erent mechanisms contribute to this imbalance.
Patients with COPD must generate more negative intrathoracic pressures in order to achieve adequate alveolar ventilation. Th e pressure output during resting breathing can be more than three times higher comparing with healthy subjects 21 . Th is means higher oxygen cost of respiration accompanied with less effi ciency. Also, inspiratory fl ow resistance is increased 22 , loss of elastic recoil causes higher relaxation volume, minute ventilation is increased up to 50% even during resting breathing, and expiratory fl ow is limited with delayed lung emptying 23, 24 . Hyperinfl ation decreases the length of the diaphragm and of the rib cage muscles with a signifi cant decrease in the length of the zone of diaphragmatic apposition, so the diaphragmatic contraction is less effective 25, 26 . Furthermore, diaphragmatic curvature is also decreased. In the situation when end-expiratory lung volume lies above 70% of the predicted total lung capacity, inspiratory muscles have to work not only against the elastic recoil of the lungs, but also against elastic recoil of the thoracic cage 27 . About half of the patients with moderate-to-severe COPD have parallel reductions in maximal inspiratory and expiratory muscle strength, possibly due to the generalized muscle weakness 27, 28 . Th e mechanisms contributing to this generalized muscle wasting are malnutrition, altered infl ammatory cytokine profi le with high plasma levels of tumor necrosis factor alpha (TNF-a) with activation of the ubiquitin-proteasome proteolytic pathway [29] [30] [31] , electrolite and blood gas abnormalities, HF 29 , weight loss 28 , and steroid myopathy 32 . Inspiratory muscle weakness in patients with CHF is a result of a complex interplay between decreased total number of diaphragmatic actin-myosin crossbridges 33 , reduction in type IIb fi bers 34 , decreased regional blood fl ow, activation of the ubiquitin-proteasome proteolytic pathway by TNF-a, decrease in various oxidative enzymes, size and number of mitochondria 35 , atrophy of the limb muscle fi bers, postcapillary pulmonary hypertension with compensatory vascular remodeling, bronchial congestion, decreased lung compliance and consequently increased work of the diaphragm up to threefold [36] [37] and, to some extent, hyperpnea that could predispose to hyperinfl ation 38, 39 .
Of note, patients with COPD have similar symptom profi les as those with HF, but dyspnea at rest is usually more pronounced.
Diagnostic Pitfalls

Echocardiography
Transthoracic echocardiography is often infl uenced by the poor acoustic windows in patients with emphysema; in a recent study, inadequate visualization caused by air trapping caused unsatisfactory results in 10.4% of all examined patients with COPD 40, 41 . Th is proportion is even greater in patients with severe and very severe airfl ow obstruction in emphysema phenotype 42 . In transesophageal echocardiography, the transducer located behind the heart enables continuous visualization of all four heart chambers without hindrance from lung even during mechanical ventilation. Of note, during transesophageal echocardiography, as well as in interventional cardiology and pulmonology, noninvasive ventilation can reduce the need for deep sedation or general anesthesia and prevent respiratory depression induced by deep sedation 43 .
Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging is the accepted reference standard for estimation of left ventricular (LV) volumes and ejection fraction. It is especially recommended in the evaluation of LV function in patients with inadequate visualization on echocardiographic images and could additionally estimate myocardial fi brosis and predict the risk of arrhythmias in COPD patients 44 .
Natriuretic peptides
Natriuretic peptides are targeted at protecting the cardiovascular system from the eff ects of volume overload. Both atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) induce vasodilatation, natriuresis and diuresis. BNP is secreted in bursts and has minimal storage, unlike ANP which can be released with minor triggers. In the setting of pressure overload or volume expansion, the synthesis of pre-proBNP in ventricular myocardium is initiated and afterwards the cleavage to proBNP and then to BNP and inactive NTproBNP follows 45 .
Both BNP and NTproBNP are useful for excluding HF in subjects presenting with acute or worsening dyspnea. Th ey also provide prognostic information as every 100 pg/mL increase in BNP level is associated with 35% increased death risk 46 . Also, BNPs are useful in monitoring the eff ects of therapeutic interventions and may be used as a tool for screening for subclinical forms of HF. Th e BNP Consensus Panel Guidelines state that BNP levels lower than 100 pg/mL have high negative and levels higher than 500 pg/mL high positive predictive value for HF. Increased levels of both BNP and NTproBNP are associated with female gender, advanced age, acute coronary syndrome without HF, sepsis, acute respiratory distress syndrome (ARDS) and right HF 45 .
Th erapeutic Challenges
ACE inhibitors or ARBs
Angiotensin-converting enzyme (ACE) inhibitors are the cornerstone of treatment in CHF. Moreover, ACE inhibition has been demonstrated to prevent smooth muscle atrophy and improve respiratory muscle strength in patients with HF 47 , and these eff ects could be especially interesting in patients with concomitant COPD. Also, cross-sectional data from 2431 hypertensive subjects found that lower limb muscle mass was larger in the ACE inhibitor group in a manner proportional to the length of use 48 . However, in a recent small randomized controlled study, Shrikrishna et al. found that fosinopril treatment for 3 months did not alter muscle atrophy signaling or exercise performance in COPD patients with quadriceps weakness 49 . Andreas et al. evaluated the eff ects of the angiotensin II receptor blocker irbesartan given over 4 months in 60 patients with COPD and FEV 1 of less than 50% of the predicted value and without obvious cardiovascular disease that would necessitate administration of an ACE inhibitor or angiotensin receptor blocker. In this study, irbesartan did not exert signifi cant eff ect on the primary end-point maximum inspiratory pressure, but there was a trend towards total lung capacity reduction -a fi nding that probably deserves prospective investigation 50 . In conclusion, despite extensive data on the eff ects of ACE and angiotensin II type-1 receptor inhibition (ARB) on systemic infl ammation and tissue metabolism, the body of evidence on the potential eff ects on pulmonary infl ammation, architecture and vasculature or skeletal muscle functional capacity in COPD, especially in the face of reduced oxygen delivery, is still insuffi cient. Nevertheless, due to the improved outcome of HF, ACE inhibitors or ARBs should not be denied in concomitant COPD. In the OPTIMIZE-HF cohort, patients with COPD were less likely to be started on ACE-Is/ARBs and aldosterone antagonists during hospital stay and were also more likely to have their ACE-Is/ARBs discontinued 51 . It should be emphasized that the regular use of ACE inhibitors does not induce bronchospasm or increased risk of cough in COPD patients.
Beta blockers
Beta blockers are still generally underused in CHF patients, especially those with concomitant COPD. According to the evidence from 12,440 patients in the ESC Heart Failure Long-Term Registry, beta blockers were prescribed to 72% of hospitalized patients with HF and 89% of patients in the outpatient setting, but only 17% of patients received targeted daily doses 52 . In a recent large sample from primary care in Scotland (N=377,439), the prevalence of established COPD in patients with HF was 25%, but only a small minority (18%) of COPD patients received beta blockers 53 . Beta-1 blockers (B1B) have 20-fold higher affi nity for beta-1 receptors (B1R) than beta-2 receptors (B2R) and, although they tend to lose sensitivity at the high end of dose ranging, patients with COPD are generally free of adverse respiratory eff ects with unchanged FEV 1 . Selective B1B do not attenuate B2R agonist-induced bronchodilatatory eff ects and may actually be benefi cial in COPD by enhancing sensitivity to exogenous beta-adrenergic stimulation. Also, recent large observational studies provide some evidence that concomitant long-term use of inhaled antimuscarinic agents or beta agonists along with cardioselective beta blockers actually reduces mortality rates and the risk of exacerbations in patients with COPD 54, 55 . According to a systematic review by Etminan et al. of nine retrospective cohort studies, beta blockers reduce mortality in COPD, most probably due to their cardioprotective eff ects 56 . However, several types of biases may have affected the cited results and one should note that studies with negative results are much less likely to be published.
Despite the data collected from meta-analyses, which strongly suggest that selective B1B should not be withheld in patients with mild to severe COPD and HF because their benefi ts by far outweigh the risks 57, 58 , beta blockers are less prescribed before admission (21.1% vs. 23.8%, p=0.055) in COPD patients, and remain underutilized at discharge (p<0.001) 59 . Carvedilol is the only non-cardioselective beta blocker approved for treating HF. Since there are no robust data supporting the safety in patients with moderate or severe airways disease, it should be avoided when possible in patients with COPD, especially during acute exacerbations.
In conclusion, cardioselectivity is paramount, and therefore metoprolol, bisoprolol and in particular nebivolol should be the fi rst choice treatment.
Inhaled beta-2 agonists
For decades, inhaled beta-2 agonists were strongly associated with adverse cardiac eff ects in COPD patients with pre-existing cardiovascular disease and an increased risk of CHF decompensation (adjusted OR 3.42; 95% CI 1.99 to 5.86), also with all-cause mortality in patients with CHF 60 . Au et al. found direct association between the number of canisters of beta agonist used and the risk of and death from all causes, suggesting caution using beta agonists in patients with left ventricular systolic dysfunction 61 . One might argue that the use of beta agonists, short-acting beta agonists (SABA) in particular, in acute setting merely refl ects the degree of dyspnea. In the ACQUIP case-control study, beta agonists in patients with HF were associated with the risk of hospitalization, but adjustment for cardiovascular morbidity, age, beta blocker use, COPD severity and smoking burden made the diff erence nonsignifi cant 62 . In short, the poor patient outcomes attributed to beta agonists may actually refl ect symptom burden in COPD.
Since long-acting beta agonists (LABA) or/and long-acting antimuscarinic agents (LAMA) are the cornerstone of COPD treatment in all stages for decreasing exacerbation rates, improving lung function and quality of life, prescribing only SABA and/or short-acting muscarinic antagonists (SAMA) for symptom relief and avoiding treating COPD when coexisting with HF would be as erroneous as denying beta blockers to patients with HF.
Th ere is additional concern of triggering supraventricular and ventricular arrhythmias by LABA, LAMA and their combinations. Multifocal atrial tachycardia (MAT), atrial fi brillation and ventricular arrhythmias often complicate the course of COPD, in particular during acute exacerbations. MAT is often associated with the use of theophylline, pulmonary embolism, hypoxemia, and also other disorders such as hypokalemia or hypomagnesemia, and chronic renal failure 63 . Th e largest trial of 1429 patients with COPD found that the administration of formoterol or salmeterol, the two most often administered LABAs, did not result in a statistically signifi cant increase in atrial arrhythmias 64 .
One of the most important risk factors of arrhythmias is acute respiratory failure or, in particular, worsening of chronic respiratory failure during acute exacerbations. One of the most important decisions in the acute clinical setting is well-timed noninvasive ventilation.
Conclusion
Both HF and COPD are global epidemics, especially in the elderly. Both diseases are chronic, progressive, and share many common pathways of low grade systemic infl ammation. Th e prevalence of coexisting HF and COPD is yet unknown and most certainly underestimated. Understanding both diseases with the use of proper diagnostic tools is mandatory in order to achieve earlier treatment and better long-term prognosis. Concurrent COPD may play part of the missing puzzle in the complex pathophysiology of HF, and vice versa. Considering the high prevalence of ventricular dysfunction in COPD, routine assessment with either BNP or echocardiography should be considered in COPD patients. On the other hand, pulmonary function tests should be performed in all HF patients. Th erefore, closer collaboration between pulmonologists and cardiologists should be warranted in the future. Also, there is an urgent need for large prospective randomized trials on long-term eff ects of diff erent classes of currently recommended drugs including patients with more advanced disease(s), including those with frequent exacerbations, patients with severe impairment of lung function, heavy symptoms, or those with the asthma and COPD overlap syndrome.
